Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo

被引：0
|
作者：
Hao Liu
Sanbao Ruan
Margaret E. Larsen
Congcong Tan
Bolin Liu
Hui Lyu
机构：
[1] Louisiana State University (LSU) Health Sciences Center,Departments of Interdisciplinary Oncology and Genetics, Stanley S. Scott Cancer Center, School of Medicine
[2] Affiliated Cancer Hospital & Institute of Guangzhou Medical University,undefined
来源：
Biological Procedures Online | / 25卷
关键词：
Therapeutic resistance; HER2-targeted therapy; In vivo tumor models; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
    Liu, Hao
    Ruan, Sanbao
    Larsen, Margaret E.
    Tan, Congcong
    Liu, Bolin
    Lyu, Hui
    BIOLOGICAL PROCEDURES ONLINE, 2023, 25 (01)
  • [2] Herceptin-resistant breast cancer cells exhibits distinct sensitivity to lapatinib in in vivo tumor xenograft models
    Ruan, Sanbao
    Liu, Hao
    Lyu, Hui
    Tan, Congcong
    Liu, Bolin
    CANCER RESEARCH, 2022, 82 (12)
  • [3] The erbB3-and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells
    Lyu, Hui
    Yang, Xiao He
    Edgerton, Susan M.
    Thor, Ann D.
    Wu, Xiaoying
    He, Zhimin
    Liu, Bolin
    ONCOTARGET, 2016, 7 (03) : 2921 - 2935
  • [4] Anthocyanins inhibit trastuzumab-resistant breast cancer in vitro and in vivo
    Li, Xin
    Xu, Jinmei
    Tang, Xi
    Liu, Yilun
    Yu, Xiaoping
    Wang, Zhi
    Liu, Weihua
    MOLECULAR MEDICINE REPORTS, 2016, 13 (05) : 4007 - 4013
  • [5] In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells
    Nahta, R
    Esteva, FJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) : 186 - 190
  • [6] In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells
    Rita Nahta
    Francisco J. Esteva
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 186 - 190
  • [7] Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer
    Araki, Kazuhiro
    Fukada, Ippei
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Iwase, Takuji
    Ito, Yoshinori
    CLINICAL BREAST CANCER, 2015, 15 (06) : 432 - 439
  • [8] LC-HRMS-based global metabolomics profiling unravels the distinct metabolic signature of lapatinib-resistant and trastuzumab-resistant HER2+breast cancer cells
    Hermawan, Adam
    Windarsih, Anjar
    Putri, Dyaningtyas Dewi Pamungkas
    Fatimah, Nurul
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2025, 253
  • [9] Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
    Nahta, Rita
    Yuan, Linda X. H.
    Du, Yi
    Esteva, Francisco J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (02) : 667 - 674
  • [10] Role of trastuzumab in the combination treatment for a HER2-positive trastuzumab-resistant gastric cancer xenograft model
    Shu, Sei
    Yamashita-Kashima, Yoriko
    Yanagisawa, Mieko
    Moriya, Yoichiro
    Harada, Naoki
    CANCER RESEARCH, 2015, 75
12345